ATAlla A. Tarasova

Alla A. Tarasova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alla A. Tarasova has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Post-vaccination immunity against hepatitis B in children with Down syndrome

    by A. Yu. Chirkova, E. G. Novopoltseva, A. A. Tarasova, I. G. Strelkova, I. S. Baklanova, E. Yu. Baskakova, A. S. Veselova, A. Medvedeva, А. Ю. Чиркова, Е. Г. Новопольцева, et al.

    Relevance. An urgent task of modern medicine is to assess the effectiveness of the immune response to hepatitis B vaccination in children with Down syndrome. Studies show that most children with Down syndrome do not develop sufficient levels of protective antibodies after standard hepatitis B vaccination. Assessing the effectiveness of the immune response will allow for the development of personalized vaccination programs for children with Down syndrome. Objective: to assess the effectiveness of the immune response to hepatitis B vaccination in children with Down syndrome by studying the concentration of specific antibodies in their blood serum and comparing the results with their vaccination status. Materials and methods. A cross-sectional cohort study was performed with the participation of 102 children with Down syndrome aged from 1 to 17 years. The concentration of IgG antibody titers to hepatitis B was analyzed, based on age and vaccination status (full, partial vaccination, no vaccination). Results. 73 (71,6 %) children had completed hepatitis B vaccination among all the subjects. The concentration of hepatitis B antibodies in children with Down syndrome decreases significantly with age, reaching a titer below 10 mIU/ml in most adolescents over 12 years of age. In children with complete vaccination in the 1–5 years group, the geometric mean of antibody titers was 24.5 mIU/ml, in the 6–11 years group, it was 26.7 mIU/ml, while in children aged 12–17 years, the antibody titers were below the protective threshold, with a geometric mean of 2.13 mIU/ml, indicating the need for further revaccination under certain conditions. Correlation analysis revealed a negative relationship between age and antibody levels (r = −0.3205, p = 0.0057). Children with Down syndrome do not have an epidemiological advantage for hepatitis B in “indicator” groups Conclusion. Among children with Down syndrome aged 12 years and older who have received a full course of hepatitis B vaccination, there is a very high percentage of those who do not have a p rotective antibody titer. It is recommended to develop a personalized approach to revaccination and monitor post-vaccination antibodies to maintain an adequate level of protection.

  • Open Access

    Approaches to the diagnosis of immunodeficiency disorders in children with Down syndrome

    by A. Yu. Chirkova, E. G. Novopoltseva, A. A. Tarasova, K. Yu. Ozhgikhin, A. S. Veselova, I. D. Morozov, U. A. Klokova, H. F. Aksyanova, N. Yu. Smelikova, E. Yu. Baskakova, et al.

       Relevance. Down syndrome is one of the most common genetic diseases worldwide. People with this syndrome are at risk for developing immunodeficiency conditions. The article discusses the results of a study of TREC and KREC concentrations in children with Down syndrome.  The aim of the study was to determine the concentration of TREC and KREC in children with Down syndrome compared with healthy children.   Materials and methods. A prospective study was conducted to determine the content of TREC and KREC in the bloo d of children and adolescents with Down syndrome.   Results. It was found that the co ncentration of TREС in children with Down syn drome is significantly lower than in healthy children of the appropriate age, which indicates a violation in the development of the T-cell link of immunity. A similar pattern is observed for KREС levels, which indicates a violation of the maturation of B-lymphocytes responsible for the synthesis of antibodies.   Conclusion. This study highlights the importance of early diagnosis and monitoring of the immune status in children with Down syndrome by determining the conc entration of TREС and KREС, which will allow timely corrective measures and prevent the development of complications.


  • Vaccination against pneumococcal infection in patients with diabetes mellitus

    by Tarasova A.A. Tarasova, Kostinov M.P. Kostinov, Novopoltseva E.G. Novopoltseva

  • Open Access

    Features of the course of pollen allergy in children in the Nizhny Novgorod region

    by E. Yu. Baskakova, A. A. Tarasova, G. A. Savichev, E. G. Novopoltseva, V. V. Meshcheryakova, A. A. Shevchenko, E. V. Pogodina, A. M. Aldabergenova, E. V. Timofeeva, N. E. Efimov, et al.

    Due to its widespread distribution, the problem of pollen allergy does not lose its relevance for practical healthcare: the variety of clinical forms, the possibility of polyvalent sensitization and pathogenetic treatment in the form of allergen-specific immunotherapy determine the importance of studying its clinical and epidemiological features.Materials and methods. A retrospective analysis of 119 discharge summaries of children with diagnoses of “Allergic rhinoconjunctivitis”, “Bronchial asthma”, “Atopic dermatitis”, occurring with clinically significant pollen sensitization, was carried out in the period 2015–2022. The prevalence, clinical features, prevailing symptoms and atopic comorbidity of patients with pollen allergy living in the Nizhny Novgorod region were assessed.Results. Pollen allergy is characterized by a variety of clinical manifestations, which are mainly represented by allergic rhinoconjunctivitis, bronchial asthma, and oral allergic syndrome. In the study, in the majority of patients, polyvalent sensitization was combined with a pronounced variety of products that provoke oral allergic syndrome. Manifestations of pollen allergies requiring seeking medical help are equally distributed among residents of Nizhny Novgorod and the region’s villages.Conclusions. Clinical and epidemiological features of the course of pollen allergy are of great interest to the practicing physician. The variety of manifestations of pollen allergies determines the need for a clinically effective treatment method, which today is ASIT. One of the needs of modern healthcare is to increase the awareness of primary care physicians about atopic diseases, incl. pollen allergy, with the aim of timely referral of patients to a specialist. Currently, allergen-specific immunotherapy is the most effective method of treating manifestations of pollen allergies.

  • Open Access

    Pneumococcal Vaccine in Adults with Bronchopulmonary Pathology: from Prevention to Treatment

    by A. M. Kostinov, A. A. Tarasova, K. V. Mashilov

    Relevance. Community-acquired pneumonia and chronic obstructive pulmonary disease (COPD) remain a serious public health problem in all respects today.Aims. To summarize the studies of domestic authors on the study of the effect of pneumococcal polysaccharide vaccine on various parts of the immune system and their relationship with the clinical course of the disease in patients with COPD and community-acquired pneumonia. We also consider it necessary to discuss the possible mechanisms of therapeutic effects after the introduction of a monovaccine against S. pneumoniae, as well as when it is combined with vaccines against Haemophilus influenzae type b infection, and the effectiveness of various vaccination regimens, including complex ones.Conclusions. Convincing arguments are presented proving that the introduction of vaccines against respiratory infections can have not only a reventive value, but also a therapeutic effect, accompanied by a transient restoration of the immune system parameters, as well as a reduction in the contamination or elimination of S. pneumoniae in patients with chronic pathology of the bronchopulmonary system.

  • Open Access

    Approaches to Vaccination of Patients with Diabetes Mellitus and Obesity in the Current Epidemiological Situation

    by A. А. Tarasova, M. P. Kostinov, V. V. Mescheriakova, M. A. Kvasova, T. A. Smirnova

    Relevance. To date, there is ample evidence that diabetes mellitus (DM) and obesity are predictors of a severe course and adverse outcome of COVID-19. The SARS-CoV-2 virus is known to have deleterious effects on the pancreas, exacerbating insulin resistance The SARS-CoV-2 virus is known to have deleterious effects on the pancreas, exacerbating insulin resistance. Long-term data have been accumulated regarding pneumococcal infection and influenza, both of which are severe in patients with diabetes and obesity. The aim is to analyze scientific publications on the problems of vaccinating patients with diabetes and obesity against SARS-CoV-2, pneumococcal infection, and influenza. Conclusions. Vaccination against COVID-19 in patients with DM and obesity is an effective preventive measure. Experience with vaccination against COVID-19 using the following vaccines: Moderna mRNA-1273, Pfizer BioNTech, BNT162b2, AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience, Sputnik V showed similar safety and efficacy profiles among obese and DM patients and those at risk. Researchers in numerous publications have emphasized the importance of routine vaccination for people living with diabetes amid a pandemic of a new coronavirus infection. Researchers in numerous publications have emphasized the importance of routine vaccination for people living with diabetes in the face of a new coronavirus pandemic. Analysis of the literature reviewed in this review suggests that vaccination against SARS-CoV-2, especially for those at risk, will be an intensive area of research in the coming years and that vaccination against coronavirus infection is likely to be routine for people with diabetes and obesity.


  • IMPACT OF COVID-19 ON PREGNANCY OUTCOME AND EVALUATION OF SARS-CoV-2 VACCINATION IN PREGNANT AND BREASTFEEDING WOMEN

    by M.P. Kostinov, M.A. Kvasova, A.A. Tarasova, E.M. Kozlova, E.G. Novopoltseva

    Aim of the study: to discuss available information on vaccination of pregnant and breastfeeding women against COVID-19. Pregnant women with SARS-CoV-2 infection are at high risk of developing severe COVID-19 and adverse outcomes due to increased rates of preterm birth, caesarean section, and neonatal admissions to the intensive care unit. Concomitant chronic diseases increase the number of maternal and fetal complications. Taking into account the passive immunization of the newborn by transplacental transfer of maternal protective antibodies into the fetus and newborn blood circulation and then through breast milk, the role of vaccination in pregnant and breastfeeding women increases. Conclusions: after an individual risk-benefit assessment, COVID-19 vaccine should be recommended for pregnant and breastfeeding women.


  • Approaches to vaccination against coronavirus infection in patients with autoimmune inflammatory rheumatic diseases

    by A.A. Tarasova, M.P. Kostinov, M.A. Kvasova

    Подходы к вакцинации против новой коронавирусной инфекции у пациентов с аутоиммунными воспалительными ревматическими заболеваниями

  • VACCINATION OF CHILDREN AGAINST A NOVEL CORONAVIRUS DISEASE AND IMMUNIZATION TACTICS IN PATIENTS WITH CHRONIC DISEASES

    by A.A. Tarasova, M.P. Kostinov, M.A. Kvasova

    The COVID-19 pandemic has had a huge impact on health care, economy and society around the world. At this stage of time, the cohort of school-age children from 7 to 14 years old has the highest number of positive tests for coronavirus infection, as well as an aggravation of the course of COVID-19 in the pediatric population. To stop the increase in cases of severe forms of infection, hospitalization and deaths, mass vaccination is required, including among the child population. Several vaccines against SARS-CoV-2 have been approved and used in children and adolescents worldwide, and a clinical trial of a domestic drug is being completed in Russia. The tactics of vaccination of children with chronic diseases are proposed.


  • Open Access

    Vaccination against pneumococcal infection in patients with chronic kidney disease

    by A. A. Tarasova, K. V. Mashilov, V. B. Polishchuk, A. A. Ryzhov

    Вакцинация против пневмококковой инфекции пациентов с хронической болезнью почек